Andrea Matucci Francesco Liotta Emanuele Vivarelli Laura Dies Francesco Annunziato Marie Pierre Piccinni Francesca Nencini Sara Pratesi Enrico Maggi Alessandra Vultaggio
10.3389/fimmu.2018.01198
Front Immunol
2018 May 29;9:1198.
gleich’s syndrome angioedema anti-interleukin-5 biological agents hypereosinophilia mepolizumab
CC BY
https://pubmed.ncbi.nlm.nih.gov/29896203/
Angioedema / drug therapy Antibodies, Monoclonal, Humanized / administration & dosage Fever / drug therapy Hypereosinophilic Syndrome / drug therapy
Angioedema / drug therapy Antibodies, Monoclonal, Humanized / administration & dosage Fever / drug therapy Hypereosinophilic Syndrome / drug therapy Case Reports Adult Angioedema / blood Angioedema / immunology Angioedema / pathology Antibodies, Monoclonal, Humanized / adverse effects Fever / blood Fever / immunology Fever / pathology Humans Hypereosinophilic Syndrome / blood Hypereosinophilic Syndrome / immunology Hypereosinophilic Syndrome / pathology Immunoglobulin M / blood Immunoglobulin M / immunology Interleukin-5 / antagonists & inhibitors Interleukin-5 / blood Interleukin-5 / immunology Leukocyte Count Male Antibodies, Monoclonal, Humanized IL5 protein, human Immunoglobulin M Interleukin-5 mepolizumab
PMC5986952
29896203
Efficacy and Safety of Mepolizumab (Anti-Interleukin-5) Treatment in Gleich's Syndrome
2018